青海春天药用资源科技股份有限公司董事会议事规则 第二章 董事会的组成 第二条 公司董事会是公司经营管理的决策机构，在《公司章程》和股东大 会的授权范围内负责公司发展目标和重大经营活动的决策。 第三条 董事会由七名董事组成，其中董事四名，独立董事三名（其中至少 一名为会计专业人士）。董事会设董事长一人，由全体董事的过半数选举产生， 是公司法定代表人。 第四条 公司董事会下设战略委员会、提名委员会、审计委员会、薪酬与考 核委员会四个专门委员会，各委员会依据《公司章程》以及各自工作规则运作。 青海春天药用资源科技股份有限公司 董事会议事规则 （2023 年 12 月修订） 第一章 总则 第一条 为进一步规范青海春天药用资源科技股份有限公司（以下简称"我 公司"）董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责， 提高董事会规范运作和科学决策水平，根据《公司法》、《证券法》、《上市公司治 理准则》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管 指引第 1 号-规范运作》及《公司章程》等有关规定，制订本规则。 第五条 董事会下设董事会秘书办公室（以下简称"董秘办"），协助董事 长处理董事 ...

股票代码：600381 股票简称：青海春天 公告编号：2023-030 青海春天药用资源科技股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 股东 | 是否为控 | 本次质 | 是否为 | 是否补 | 质押起 | 质押到 | | 占其所 | 占公司 | 质押融 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | 押股数 | 限售股 | 充质押 | 始日 | 期日 | 质权人 | 持股份 | 总股本 | 资资金 | | | | | | | | | | 比例 | 比例 | 用途 | | 西 藏 | 是 | 2,000 | 否 | 否 | 2023- | 2024- | 云南国 际 | 10.60% | 3.41% | 项目开 | | 荣恩 | | 万股 | | | 11-21 | 11-20 | 信托有 限 | | | 发 | | | | | | | | | 公司 | | ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥53,289,081.38, representing a 129.10% increase compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2023 reached ¥160,712,654.06, an increase of 24.93% compared to ¥128,645,957.46 in the same period of 2022[21]. - The net profit attributable to shareholders was -¥19,740,514.59, with a year-to-date net profit of -¥70,331,228.73[5]. - Net profit for the first three quarters of 2023 was a loss of ¥68,576,421.15, compared to a loss of ¥75,403,109.87 in the same period of 2022, showing an improvement of 9.73%[22]. - Basic and diluted earnings per share for Q3 2023 were both -¥0.034, with a year-to-date figure of -¥0.120[6]. - Basic and diluted earnings per share for the first three quarters of 2023 were both -0.120, slightly better than -0.128 in the same period of 2022[23]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥8,962,743.45[6]. - Net cash flow from operating activities for Q3 2023 was $8,962,743.45, a significant improvement from a net outflow of $20,357,176.51 in Q3 2022[26]. - Cash paid for operating activities totaled $170,177,883.30, down from $196,434,823.09 in Q3 2022[26]. - Total cash inflow from investment activities was $60,089,667.08, compared to $623,921,075.12 in the same period last year[26]. - Cash outflow from investment activities totaled $71,014,967.19, resulting in a net cash flow of -$10,925,300.11 for Q3 2023, down from a positive $34,780,001.12 in Q3 2022[26]. - The company reported a net cash decrease of $6,749,165.61 for Q3 2023, contrasting with an increase of $14,883,799.99 in Q3 2022[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,520,345,780.92, a decrease of 2.49% from the end of the previous year[6]. - As of September 30, 2023, the total assets of the company amounted to CNY 1,520,345,780.92, a decrease from CNY 1,559,229,152.99 at the end of 2022, reflecting a decline of approximately 2.1%[15]. - The company's current assets totaled CNY 761,618,090.69, down from CNY 816,003,528.06, indicating a decrease of about 6.7%[17]. - Total liabilities as of the end of the third quarter of 2023 amounted to ¥55,992,026.91, compared to ¥26,298,977.83 at the end of the same period in 2022, indicating a significant increase[22]. - The total liabilities of the company were not explicitly stated, but current liabilities included accounts payable of CNY 16,467,410.00, up from CNY 2,672,389.74, showing a significant increase[17]. Equity and Investments - The equity attributable to shareholders decreased by 4.59% to ¥1,462,600,343.67 compared to the end of the previous year[6]. - Total equity attributable to shareholders of the parent company was ¥1,462,600,343.67, down from ¥1,532,931,572.40 in the previous year[22]. - The company has a long-term equity investment valued at CNY 172,708,109.45, slightly down from CNY 172,824,966.22, indicating a marginal decrease[17]. Operational Highlights - The company reported a significant increase in revenue from liquor and traditional Chinese medicine services as the main driver for the revenue growth[10]. - Research and development expenses for the first three quarters of 2023 were ¥7,554,555.90, slightly up from ¥7,356,360.50 in 2022, indicating continued investment in innovation[21]. - The company reported a financial expense of -¥74,903.47 in the first three quarters of 2023, a significant improvement compared to ¥691,604.64 in the same period of 2022[21]. - The company has not reported any new product launches or significant market expansion strategies during this period[21]. - The company did not report any new product launches or significant market expansions during this quarter[28]. Other Financial Metrics - Non-recurring losses for the reporting period included a loss from the disposal of non-current assets amounting to -¥19,388.28[8]. - The company received government subsidies totaling ¥171,826.34 during the reporting period[8]. - The weighted average return on net assets was -1.3%, a slight increase of 0.18 percentage points compared to the previous year[6]. - Cash and cash equivalents were reported at CNY 161,941,283.99, a decrease from CNY 168,690,449.60, representing a decline of approximately 4.4%[15]. - Accounts receivable increased to CNY 62,767,471.38 from CNY 55,367,840.10, marking an increase of about 13.5%[15]. - Inventory decreased to CNY 304,777,334.66 from CNY 333,495,051.35, reflecting a decline of approximately 8.6%[15]. - The company's non-current assets totaled CNY 758,727,690.23, an increase from CNY 743,225,624.93, indicating a growth of about 2.3%[17]. - The company’s fixed assets increased to CNY 280,254,004.18 from CNY 274,955,062.12, reflecting a growth of about 1.2%[17]. - The company reported a decrease in other receivables to CNY 10,522,211.79 from CNY 11,995,395.78, a decline of approximately 12.3%[15].

股票代码：600381 股票简称：青海春天 公告编号：2023-029 青海春天药用资源科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、 参加人员 重要内容提示： 问题征集方式：投资者可于 2023 年 10 月 12 日 15:00 前，提前将需要了解的 情况和有关问题通过电子邮件发送至公司邮箱 investor@verygrass.com。公司将在本 次业绩说明会上对投资者普遍关注的问题进行交流。 一、 说明会类型 青海春天药用资源科技股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体披露了《2023 年半年度 报告》。 为了便于广大投资者更全面深入了解公司 2023 年半年度生产经营、发展情况及未 来规划等，公司决定通过网络互动的方式召开 2023 年半年度业绩说明会，就投资者普 遍关注的问题进行交流。 二、 说明会召开的时间、地点 1.召开时间：2023 年 10 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 107.42 million, representing a 1.93% increase compared to CNY 105.39 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 50.59 million, compared to a loss of CNY 48.94 million in the previous year, indicating a continued decline in profitability[21]. - The net cash flow from operating activities was a negative CNY 24.47 million, worsening from a negative CNY 16.24 million in the same period last year[21]. - The total assets at the end of the reporting period were CNY 1.53 billion, down 1.65% from CNY 1.56 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased to CNY 1.48 billion, a decline of 3.3% from CNY 1.53 billion at the end of the previous year[21]. - The basic earnings per share for the first half of 2023 was -CNY 0.086, slightly worse than -CNY 0.083 in the same period last year[22]. - The weighted average return on net assets was -3.35%, a decrease of 0.63 percentage points compared to -2.72% in the previous year[22]. - Total revenue for the reporting period was CNY 107.42 million, a 1.93% increase year-on-year, with core business revenue at CNY 103.22 million, growing 0.44%[36]. - Sales expenses rose to CNY 89.24 million, a 29.23% increase year-on-year, contributing to an operating loss of CNY 47.06 million[36]. Business Operations and Strategy - The company has not disclosed any plans for new product development or market expansion in this report[21]. - The company is focusing on upgrading the "Tinghua" and "Duhua" high-end liquor products, with new product launches expected in the third quarter[30]. - The company is enhancing its marketing efforts and expanding distribution channels to improve sales performance[29]. - The company is optimizing and regulating its distributor network to support future marketing and sales efforts[30]. - The company has established a strategic partnership with Yibin Tinghua for exclusive sales of high-end liquor series, focusing on self-operated and distributor sales channels[32]. - The company is enhancing brand influence through multi-channel marketing efforts, including major media outlets and targeted advertising[39]. - The company continues to strengthen cooperation with distributors to expand sales channels and ensure mutual benefits[39]. - The company has opened 9 "Tinghua" experience stores in cities including Beijing, Tianjin, and Chengdu, with 7 more under construction, enhancing consumer engagement with the product[31]. Market Environment - The domestic GDP for the first half of 2023 was 59.30 trillion yuan, with a year-on-year growth of 5.5%[26]. - The retail sales of consumer goods reached 22.76 trillion yuan, a year-on-year increase of 8.2%[26]. - The government has introduced favorable policies for the traditional Chinese medicine industry, providing a positive market environment[27]. Financial Health and Risks - The report includes a risk statement regarding potential external environment risks and internal management risks that may affect future performance[6]. - The company faces risks including policy market risks, market competition risks, and internal management risks, which may impact strategic development and operational plans[55]. - The company plans to enhance internal control execution and supervision to mitigate risks related to product quality, food safety, and decision-making errors[56]. - The company maintains a healthy financial structure with low debt levels, ensuring smooth operations and strategic planning[34]. Research and Development - Research and development expenses increased by 9.21% to CNY 3.25 million, indicating a focus on innovation[42]. - The company has applied for an international invention patent related to a new alcohol composition aimed at health benefits, indicating significant future product potential[39]. Subsidiaries and Investments - The company has a total of 9 subsidiaries included in the consolidated financial statements for 2023[138]. - The company established two joint ventures in Tibet, each holding 51% equity, to enhance sales channels, which will aid future business development[40]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 55,530[82]. - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 194,115,194 shares, accounting for 33.07% of the total shares[85]. - The second-largest shareholder, Dantian, holds 56,762,789 shares, representing 9.67% of the total shares[85]. - No profit distribution or capital reserve transfer plans were proposed for the half-year, with no dividends or stock bonuses planned[65]. Compliance and Governance - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[139]. - The company has not reported any significant changes in its share capital structure during the reporting period[81]. - The company has not reported any major changes in the board of directors or senior management during the reporting period[87]. Accounting Policies - The company follows specific accounting policies for bad debt provisions, inventory valuation, and revenue recognition, among others[140]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position as of June 30, 2023[141]. - The company recognizes revenue when control of goods or services is transferred to customers, typically at the point of delivery[191].

股票代码：600381 股票简称：青海春天 公告编号：2023-018 青海春天药用资源科技股份有限公司 关于参加 2023 年青海辖区上市公司投资者网上集体接待日暨 2022 年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 6 月 2 日（星期五）14:00-17:00 会议召开地点："全景路演"（网址：https://rs.p5w.net） 会议召开方式：网络互动方式 为进一步加强与投资者的互动交流，青海春天药用资源科技股份有限公司（以下 简称"公司"）将参加由青海证监局、青海证券业协会与深圳市全景网络有限公司联 合举办的"2023 年青海辖区上市公司投资者集体接待日暨 2022 年度业绩说明会活动"， 现将相关事项公告如下： 一、活动概况 1.召开时间：2023 年 6 月 2 日（星期五）14:00-17:00 2.召开方式：网络远程方式 3.召开地点：投资者可登录"全景路演"网站（https://rs.p5w.net），或关注 微信公众号：全景财经 ...

股票代码：600381 股票简称：青海春天 公告编号：2023-018 一、活动概况 1.召开时间：2023 年 6 月 2 日（星期五）14:00-17:00 青海春天药用资源科技股份有限公司 关于参加 2023 年青海辖区上市公司投资者网上集体接待日暨 2022 年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为进一步加强与投资者的互动交流，青海春天药用资源科技股份有限公司（以下 简称"公司"）将参加由青海证监局、青海证券业协会与深圳市全景网络有限公司联 合举办的"2023 年青海辖区上市公司投资者集体接待日暨 2022 年度业绩说明会活动"， 现将相关事项公告如下： 特此公告。 会议召开时间：2023 年 6 月 2 日（星期五）14:00-17:00 会议召开地点："全景路演"（网址：https://rs.p5w.net） 会议召开方式：网络互动方式 2.召开方式：网络远程方式 3.召开地点：投资者可登录"全景路演"网站（https://rs.p5w.net），或关注 微信公众 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥56,346,354.72, representing a decrease of 25.09% compared to the same period last year[5] - The net profit attributable to shareholders of the listed company was a loss of ¥28,718,503.69, with no applicable percentage change due to the loss[5] - The net cash flow from operating activities was a negative ¥27,687,230.10, primarily due to the decline in operating revenue[10] - Basic and diluted earnings per share were both -0.0489 yuan, with a weighted average return on equity of -1.89%, down by 0.59 percentage points year-on-year[6] - Net profit for Q1 2023 was a loss of CNY 27,835,471.27, compared to a loss of CNY 23,568,451.50 in Q1 2022, indicating a deterioration of about 18.5%[23] - The total comprehensive loss for Q1 2023 was CNY 27,835,471.27, compared to a loss of CNY 23,568,451.50 in Q1 2022, reflecting an increase in overall losses[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,555,335,295.75, a decrease of 0.25% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 1,555,335,295.75, slightly down from RMB 1,559,229,152.99 at the end of 2022[18] - Total liabilities increased to ¥50,240,591.86 from ¥26,298,977.83, indicating a significant rise of 91.1%[17] - The company's equity attributable to shareholders decreased to RMB 1,504,213,068.71 from RMB 1,532,931,572.40, a decline of 1.9%[18] Revenue and Costs - Total operating revenue for Q1 2023 was RMB 56,346,354.72, a decrease of 25.1% compared to RMB 75,221,543.33 in Q1 2022[21] - Total operating costs for Q1 2023 were RMB 84,161,826.81, down from RMB 99,888,883.12 in Q1 2022, representing a reduction of 15.8%[21] - The decline in operating revenue was mainly attributed to a decrease in sales due to product upgrades in the beverage segment[10] - Total revenue from sales and services received in Q1 2023 was CNY 48,116,521.39, down from CNY 93,340,866.36 in Q1 2022, representing a decline of approximately 48.5%[24] Cash Flow and Investments - The company's cash and cash equivalents decreased to RMB 140,098,797.46 from RMB 168,690,449.60, a decline of 17%[15] - Cash and cash equivalents at the end of Q1 2023 were CNY 140,098,797.46, down from CNY 177,775,839.00 at the end of Q1 2022, a decrease of approximately 21.2%[26] - Investment cash inflow for Q1 2023 was CNY 20,038,652.91, significantly lower than CNY 136,614,403.68 in Q1 2022, a decrease of about 85.3%[26] Shareholder Information - The company reported a total of 56,195 common shareholders at the end of the reporting period[11] - The largest shareholder, Tibet Rong'en Technology Co., Ltd., held 33.07% of the shares, with a total of 194,115,194 shares[12] Expenses - The company reported a significant increase in sales expenses to RMB 49,895,221.00 from RMB 48,276,232.31, an increase of 3.4%[21] - R&D expenses for Q1 2023 were CNY 2,036,313.84, an increase from CNY 1,416,075.33 in Q1 2022, reflecting a growth of approximately 43.7%[22] - The company incurred financial expenses of CNY -251,507.36 in Q1 2023, compared to CNY -128,069.15 in Q1 2022, indicating an increase in financial costs[22] Other Income - Non-operating income included government subsidies of ¥184,197.38, while non-recurring losses from asset disposal amounted to ¥16,637.78[7] - The company received tax refunds amounting to CNY 142,116.61 in Q1 2023, compared to CNY 1,712.11 in Q1 2022, showing a significant increase in tax-related cash inflows[25]

Financial Performance - The company's consolidated net profit attributable to shareholders for 2022 was -287,548,928.51 RMB, while the parent company's net profit was -215,884,196.82 RMB[4]. - Total revenue for 2022 reached 160,178,078.61 RMB, representing a 25.37% increase compared to 2021[22]. - The net cash flow from operating activities was -31,821,162.74 RMB, showing an improvement from -63,933,807.38 RMB in the previous year[22]. - The total assets at the end of 2022 were 1,559,229,152.99 RMB, a decrease of 15.63% from the previous year[22]. - The net assets attributable to shareholders decreased by 15.80% to 1,532,931,572.40 RMB compared to the end of 2021[22]. - The net loss attributable to shareholders was 287.55 million RMB, with a non-GAAP net loss of 262.52 million RMB, indicating an increase in losses compared to the previous year[33]. - The company reported a total operating loss of 129.74 million RMB, accounting for 45.12% of the total losses, due to increased marketing expenses of 123.24 million RMB, which grew by 121.34%[37]. - The total comprehensive loss for 2022 was ¥287,550,325.75, compared to a loss of ¥248,610,919.96 in 2021, highlighting ongoing financial challenges[192]. Revenue Breakdown - The company reported a significant increase in revenue from core business activities, with a total of 155,045,737.02 RMB, up 34.52% from 2021[22]. - The company's operating revenue for 2022 was 160.18 million RMB, an increase of 25.37% year-on-year[33]. - The revenue from core business, after excluding unrelated income, was 155.05 million RMB, up 34.52% year-on-year[33]. - The health product segment, primarily focused on the sales of Cordyceps and traditional Chinese medicine, generated revenue of 4.17 million RMB, a year-on-year increase of 35.66%[37]. - The sales revenue from the liquor fast-moving consumer goods segment reached 93.64 million RMB, representing a year-on-year growth of 268.75%[36]. - The sales revenue from traditional Chinese medicine products, specifically the "Lifelong Tablets," grew by 35.66% to 41.69 million yuan[46]. - The sales of Cordyceps sinensis raw grass decreased by 66.63%, generating revenue of 19.71 million yuan[46]. Expenses and Costs - The company's marketing expenses surged by 121.34% to 123.24 million yuan, primarily due to increased market promotion costs in the fast-moving consumer goods sector[48]. - The company recognized asset impairment losses of 92.84 million RMB and credit impairment losses of 27.18 million RMB during the reporting period[33]. - Total operating costs for 2022 were ¥289,917,807.91, up 23.8% from ¥234,086,137.04 in 2021[191]. Research and Development - The research and development expenses increased by 19.29% to 11.38 million yuan, reflecting the company's commitment to innovation[48]. - The number of R&D personnel is 12, accounting for 6.9% of the total workforce[62]. - Research and development expenses increased to ¥11,377,981.32 in 2022, up from ¥9,538,458.61 in 2021, indicating a focus on innovation[194]. Governance and Compliance - The company has established a comprehensive internal governance system, ensuring compliance with laws and regulations while safeguarding shareholder interests and sustainable development[102]. - The board of directors has set up specialized committees to enhance governance and ensure effective decision-making processes[103]. - The company maintains independence from its controlling shareholders in business, financial, and operational aspects, ensuring fair treatment in related transactions[103]. - The company has established a series of regulations related to information management and disclosure, including the "Board Secretary Work System" and "Information Disclosure Management Measures," ensuring compliance with the Shanghai Stock Exchange's requirements[104]. - During the reporting period, the company did not experience any violations of information disclosure or insider trading activities[104]. Market and Strategic Initiatives - The company focused on the fast-moving consumer goods and health sectors, emphasizing innovation and product upgrades[33]. - The company plans to launch upgraded products "Sauce Aroma PLUS" and "Strong Aroma PLUS" in June 2023, which will feature at least 24 additional aroma notes and enhanced taste dimensions[35]. - The company has established joint ventures with local partners to expand sales channels, holding 51% equity in each of the new companies[36]. - The company aims to leverage the recovery of domestic consumption and pursue health-oriented product offerings, focusing on innovation in liquor quality and taste[93]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 68,470, an increase from 56,195 at the end of the previous month[156]. - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 33.07% of the shares, amounting to 194,115,194 shares, with 151,110,000 shares pledged[158]. - The second-largest shareholder, Xiao Rong, holds 9.67% of the shares, totaling 56,762,789 shares, with 40,942,959 shares pledged[159]. Environmental and Social Responsibility - The company invested 468,000 RMB in environmental protection during the reporting period[136]. - The company is exploring solar power generation projects and plans to utilize idle factory roof resources for distributed photovoltaic power generation[138]. - The company has implemented measures to reduce carbon emissions, including using solar preheating systems and recovering boiler flue gas waste heat[138]. - The company actively participates in community public welfare activities and promotes a harmonious community[139]. - The company emphasizes product quality and environmental protection as part of its corporate social responsibility initiatives[139].

2022 年第三季度报告 证券代码：600381 证券简称：青海春天 青海春天药用资源科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | | 年初至报告期末 | | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 23,259,792.69 | -32.44 | 128,645,957.46 | 57.90 | | 归属于上市公司股东的 | -26,464,267.29 | 不适用 | -75,403,109.87 | 不适用 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | -26,925,671.99 | 不适用 | -77,105,51 ...